UroGen Pharma Ltd. is a biotechnology company focused on developing innovative therapies for urological cancers and disorders, particularly in the U.S. and Europe. Its lead product, UGN-101, targets upper tract urothelial carcinoma and has received FDA approval, positioning UroGen as a key player in a niche market with significant unmet medical needs.
Business Overview
UroGen generates revenue primarily through the commercialization of its FDA-approved drug UGN-101, which is priced at a premium due to its innovative delivery mechanism and efficacy in treating specific urological conditions. The company benefits from a strong patent portfolio that provides exclusivity and pricing power in a competitive landscape.
FDA approval of new indications for UGN-101
Clinical trial results for pipeline products
Partnerships or collaborations with larger pharmaceutical companies
Changes in reimbursement policies affecting oncology treatments
Risk Factors
Regulatory changes that could impact drug approval processes
Technological disruption in drug delivery methods
Emergence of new therapies from competitors targeting the same urological conditions
Pricing pressure from generic alternatives after patent expiration
High operating losses leading to cash burn
Potential need for additional financing to support R&D efforts
Macro Sensitivity
moderate - The demand for oncology drugs can be somewhat insulated from economic cycles, but overall healthcare spending is influenced by GDP growth.
Interest rates affect UroGen's cost of capital for R&D financing and can impact investor sentiment regarding high-growth biotech valuations.
minimal - The company has a strong current ratio and negative debt/equity ratio, indicating low reliance on external credit.
Profile
growth - Investors are drawn to UroGen for its potential high returns from innovative therapies in a specialized market.
high - The stock has shown significant price fluctuations, as evidenced by its 152.1% return over the past year.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
